111In-octreotide scintigraphy in oncology

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmacology

Background:

• Amine precursor uptake and decarboxylation (APUD) tumors are visualized using [123I-Tyr3]-octreotide.
• Limitations of [123I-Tyr3]-octreotide include a short half-life and high abdominal radioactivity.
• A novel somatostatin analogue, 111In-octreotide, was developed to overcome these limitations.

Purpose of the Study:

• To evaluate the efficacy of 111In-octreotide scintigraphy for in vivo tumor visualization.
• To compare the diagnostic performance of 111In-octreotide with conventional imaging techniques.
• To assess the correlation between in vivo imaging results and in vitro somatostatin receptor status.

Main Methods:

• Intravenous injection of 111In-coupled somatostatin analogue ([111In-DTPA-D-Phe1]-octreotide).
• Scintigraphic imaging to detect radioactivity accumulation in tumor sites.
• Comparison of imaging findings with conventional methods and in vitro receptor analysis.

Main Results:

• High visualization rates for various neuroendocrine tumors including gastrinomas, insulinomas, and carcinoids.
• Successful imaging of non-APUD tumors such as breast cancer, lymphomas, and granulomas.
• 111In-octreotide scintigraphy identified more tumor sites than conventional techniques in several cases.

Conclusions:

• 111In-octreotide scintigraphy is a valuable tool for visualizing a wide range of tumors, including neuroendocrine and other malignancies.
• This method offers superior detection capabilities compared to conventional imaging for certain tumor types.
• The diagnostic accuracy of 111In-octreotide imaging is supported by its correlation with tumor somatostatin receptor expression.